N 17350
Alternative Names: N-17350; NEU-001 - Onchilles PharmaLatest Information Update: 30 Apr 2026
At a glance
- Originator Onchilles Pharma
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Leucocyte elastase modulators; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 Mar 2026 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Australia (Intratumoural)(NCT07339176)
- 02 Feb 2026 Onchilles Pharma announces intention to initiate a first-in-human proof-of-concept clinical trial in Solid tumours (Monotherapy) in Australia and USA(Intratumoural, Injection), in March 2026 (NCT07339176)
- 02 Feb 2026 US FDA clears IND application of N 17350 in Solid tumor